Linagliptin Oral Composition for Moisture-Stable Dissolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing solid oral pharmaceutical compositions of linagliptin face issues with stability due to hygroscopicity and incompatibility caused by excipients like microcrystalline cellulose, croscarmellose sodium, and stearates, which also affect dissolution rate and bioavailability.
Innovation Solution
The formulation excludes these excipients and uses mannitol, sodium starch glycolate, povidone, and sodium stearyl fumarate in specific ratios, with a coating layer, to enhance stability and dissolution profile.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If microcrystalline cellulose is used as diluent, then the dosage form can be manufactured, but moisture resistance is compromised due to hygroscopicity
Solution Approach 1:
The patent removes microcrystalline cellulose from the formulation entirely, extracting the problematic hygroscopic component while maintaining the dosage form's manufacturability through alternative excipient selection
Solution Approach 2:
The patent changes the physical and chemical parameters of the diluent by selecting non-hygroscopic alternatives such as mannitol, lactose, and calcium phosphate, fundamentally altering the moisture interaction characteristics of the formulation
2Ease of manufacture
If stearates are used as lubricant, then manufacturing is facilitated, but incompatibility and degradation problems occur with DPP-4 inhibitors
Solution Approach 1:
The patent eliminates stearates from the formulation, removing the source of chemical incompatibility and degradation while maintaining adequate lubrication through alternative excipients
Solution Approach 2:
The patent introduces alternative lubricants such as magnesium stearate-free options and other compatible excipients that act as intermediaries between the DPP-4 inhibitor and the manufacturing process, preventing direct harmful interactions
3Quantity of substance
If corn starch and magnesium stearate are used in high amounts, then formulation requirements are met, but dissolution rate and bioavailability are reduced
Solution Approach 1:
The patent optimizes the quantity parameters of excipients by limiting corn starch to less than 10% and eliminating magnesium stearate, thereby changing the dissolution kinetics to favor faster drug release while still meeting formulation requirements
4Device complexity
If excipients with primary amine groups are present, then formulation can be simplified, but incompatibility and extraction problems arise
Solution Approach 1:
The patent removes excipients containing primary amine groups from the formulation, eliminating the source of incompatibility and extraction problems while maintaining formulation functionality through alternative excipient selection
Data Source
AI summary
The present invention relates to solid oral pharmaceutical compositions comprising linagliptin or a pharmaceutically acceptable salt thereof which provide enhanced stability.